| Small-molecule ferroptotic agents with potential to selectively target cancer stem cells WR Taylor, SR Fedorka, I Gad, R Shah, HD Alqahtani, R Koranne, ... Scientific reports 9 (1), 5926, 2019 | 58 | 2019 |
| Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F N Kuganesan, S Dlamini, LMV Tillekeratne, WR Taylor Journal of Biological Chemistry 297 (6), 2021 | 43 | 2021 |
| Identification and initial characterization of a potent inhibitor of ferroptosis N Kuganesan, S Dlamini, J McDaniel, VLM Tillekeratne, WR Taylor Journal of cellular biochemistry 122 (3-4), 413-424, 2021 | 15 | 2021 |
| Synthesis and Development of a Novel First-in-Class Cofilin Inhibitor for Neuroinflammation in Hemorrhagic Brain Injury SI Alaqel, S Dlamini, DA Almarghalani, A Shettigar, Q Alhadidi, ... ACS chemical neuroscience 13 (7), 1014-1029, 2022 | 10 | 2022 |
| A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics AA Al-Hamashi, R Koranne, S Dlamini, A Alqahtani, E Karaj, MS Rashid, ... Bioorganic chemistry 116, 105297, 2021 | 9 | 2021 |
| Bioactive constituents isolated from the Sri Lankan endemic plant Artocarpus nobilis and their potential to use in novel cosmeceuticals GD Liyanaararchchi, AS Perera, JKRR Samarasekera, KRR Mahanama, ... Industrial Crops and Products 184, 115076, 2022 | 7 | 2022 |
| Pharmacophore optimization of imidazole chalcones to modulate microtubule dynamics E Karaj, S Dlamini, R Koranne, SH Sindi, L Perera, WR Taylor, ... Bioorganic Chemistry 122, 105700, 2022 | 6 | 2022 |
| Regulation of ferroptosis by transcription factor E2F1 and RB N Kuganesan, S Dlamini, VLM Tillekeratne, WR Taylor Research Square, 2023 | 3 | 2023 |
| Imidazole-based anticancer agents and derivatives thereof, and methods of making and using same V Tillekeratne, A Al-Hamashi, S Dlamini, ASS Alqahtani, E Karaj US Patent 11,098,038, 2021 | 2 | 2021 |
| Mutant p53 reactivators protect breast cancer cells from ferroptosis DS Rathnayake, S Dlamini, K Elkalawozgy, LMV Tillekeratne, WR Taylor Cell Biochemistry and Function 42 (4), e4036, 2024 | | 2024 |
| Mutant p53 reactivators protect breast cancer cells from ferroptosis WR Taylor, DS Rathnayake, S Dlamini, K Elkalawozgy, LMV Tillekeratne Authorea Preprints, 2024 | | 2024 |
| In Search of Selectivity: Design, Synthesis, and Biological Evaluation of New Classes of HDAC Inhibitors LMV Tillekeratne, AA Al-Hamashi, S Dlamini, W Taylor, R Koranne, ... Proceedings 22 (1), 63, 2023 | | 2023 |
| Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F N Kuganesan, S Dlamini, V Tillekeratne, W Taylor Journal of Biological Chemistry 299 (3), S496, 2023 | | 2023 |
| Synthesis and Biological Evaluation of Anti-cancer Agents and Identification of Their Molecular Targets SM Dlamini The University of Toledo, 2022 | | 2022 |
| Inhibitor of HDAC8 reveals its potential role in maintaining mitotic spindle architecture. RA Koranne, A Al-Hamashi, S Dlamini, M Rashid, V Tillekeratne, ... MOLECULAR BIOLOGY OF THE CELL 29 (26), 2018 | | 2018 |
| Synthesis and Biological Evaluation of HDAC Inhibitors with 1-(1H-imidazol-2-yl) ethan-1-one Moiety as the Metal-Binding Group SM Dlamini University of Toledo, 2017 | | 2017 |
